Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | KHK | P50053 | 4/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908278 | 1.00 | SMO (0.46) | SMOSYKKHKMAP3K12S1PR1 | |
| SCHEMBL907875 | 1.00 | SMO (0.46) | SMOSYKKHKMAP3K12S1PR1 | |
| SCHEMBL908599 | 1.00 | SMO (0.46) | SMOSYKKHKMAP3K12S1PR1 | |
| SCHEMBL907876 | 1.00 | SMO (0.46) | SMOSYKKHKMAP3K12S1PR1 | |
| SCHEMBL908233 | 0.94 | SYK (0.40) | SMOSYKKHKMAP3K12ACACB | |
| SCHEMBL908231 | 0.94 | SYK (0.40) | SMOSYKKHKMAP3K12ACACB | |
| SCHEMBL908165 | 0.93 | SMO (0.44) | SMOSYKACACBACACAALDH1A1 | |
| SCHEMBL908470 | 0.93 | SMO (0.44) | SMOSYKACACBACACAALDH1A1 | |
| SCHEMBL908312 | 0.93 | SMO (0.42) | SMOSYKKHKMAP3K12S1PR1 | |
| SCHEMBL908311 | 0.93 | SMO (0.42) | SMOSYKKHKMAP3K12S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12601929-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2026-04-14 | — | — | US | claimed |
| EP-4388349-B1 | CONTACT LENS | COOPERVISION INT LTD (GB) | 2025-03-12 | — | — | EP | claimed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | claimed |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | claimed |
| US-12153288-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-11-26 | — | — | US | claimed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | claimed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240264469-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-08-08 | — | — | US | claimed |
| CN-118103737-A | Contact lens | 库博光学国际有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20230350228-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-02 | — | — | US | claimed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | claimed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | claimed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | claimed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| EP-1786800-A4 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORP (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1786800-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | claimed |
| WO-2006026135-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-03-09 | — | — | WO | claimed |
| US-12601929-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12403139-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2025-09-02 | — | — | US | disclosed |
| CN-119613561-A | TRPV1 nano disc protein and preparation method and application thereof | 深圳晶蛋生物医药科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4388349-B1 | CONTACT LENS | COOPERVISION INT LTD (GB) | 2025-03-12 | — | — | EP | disclosed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | disclosed |
| US-12186314-B2 | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4472615-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240390515-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12153288-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-11-26 | — | — | US | disclosed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118647364-A | Multi-dose ophthalmic compositions | 奥库里斯经营管理有限责任公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240264469-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-08-08 | — | — | US | disclosed |
| EP-4388349-A1 | CONTACT LENS | CooperVision International Limited (GB) | 2024-06-26 | — | — | EP | disclosed |
| US-20240189389-A1 | DRUG WITH PROLONGED ANALGESIC ACTION | FEDERALNOJE GOSUDARSTVENNOJE BUDZHETNOJE UCHREZHDENIE NAUKI TIKHOOKEANSKY (RU) | 2024-06-13 | — | — | US | disclosed |
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | disclosed |
| CN-118103737-A | Contact lens | 库博光学国际有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3348267-B1 | TRPV1 INHIBITOR FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230350228-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| WO-2023209329-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023148231-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis SA (CH) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4154899-A1 | DRUG WITH PROLONGED ANALGESIC ACTION | Federalnoe Gosudarstvennoe Budzhetnoje Uchrezhdenie Nauki Tikhookeansky Institut Bioorganicheskoi Khimii Im. G.B. Elyakova (RU) | 2023-03-29 | — | — | EP | disclosed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | SMO 1520/4885SYK 2213/4885KHK 2881/4885 |
| US-12601929-B2 | Contact lens | TRPM8, TRPM7, TRPM5 | SMO 3115/4885SYK 4246/4885KHK 2923/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | SMO 1476/4885SYK 2295/4885KHK 2971/4885 |
| US-20240390515-A1 | MULTIDOSE OPHTHALMIC COMPOSITIONS | SORBS1, PDCD6, PDCD2L | SMO 3716/4885SYK 1591/4885KHK 516/4885 |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | CNR2, TRPV1, CNR1 | SMO 1270/4885SYK 2576/4885KHK 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.